On Mar. 27, 2020, Amyris announced that it had completed initial testing of a leading vaccine adjuvant. In partnership with the Infectious Diseases Research Institute (IDRI) in Seattle. Amyris completed initial testing of its fermentation-derived squalene as a vaccine adjuvant.

The company was in active discussion with a leader in the pharmaceutical industry to target broad application of Amyris squalene in flu and potential COVID-19 vaccines.